284 related articles for article (PubMed ID: 23344982)
1. Quantitative prediction of the impact of drug interactions and genetic polymorphisms on cytochrome P450 2C9 substrate exposure.
Castellan AC; Tod M; Gueyffier F; Audars M; Cambriels F; Kassaï B; Nony P;
Clin Pharmacokinet; 2013 Mar; 52(3):199-209. PubMed ID: 23344982
[TBL] [Abstract][Full Text] [Related]
2. Quantitative prediction of cytochrome P450 (CYP) 2D6-mediated drug interactions.
Tod M; Goutelle S; Clavel-Grabit F; Nicolas G; Charpiat B
Clin Pharmacokinet; 2011 Aug; 50(8):519-30. PubMed ID: 21740075
[TBL] [Abstract][Full Text] [Related]
3. In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substrates.
Goutelle S; Bourguignon L; Bleyzac N; Berry J; Clavel-Grabit F; Tod M
AAPS J; 2013 Apr; 15(2):415-26. PubMed ID: 23319287
[TBL] [Abstract][Full Text] [Related]
4. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Brown HS; Galetin A; Hallifax D; Houston JB
Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
[TBL] [Abstract][Full Text] [Related]
5. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.
Kirchheiner J; Roots I; Goldammer M; Rosenkranz B; Brockmöller J
Clin Pharmacokinet; 2005; 44(12):1209-25. PubMed ID: 16372821
[TBL] [Abstract][Full Text] [Related]
6. Reliability and extension of quantitative prediction of CYP3A4-mediated drug interactions based on clinical data.
Loue C; Tod M
AAPS J; 2014 Nov; 16(6):1309-20. PubMed ID: 25274605
[TBL] [Abstract][Full Text] [Related]
7. In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics.
Jin Y; Borell H; Gardin A; Ufer M; Huth F; Camenisch G
Eur J Clin Pharmacol; 2018 Apr; 74(4):455-464. PubMed ID: 29273968
[TBL] [Abstract][Full Text] [Related]
8. Development of an in vitro system with human liver microsomes for phenotyping of CYP2C9 genetic polymorphisms with a mechanism-based inactivator.
Flora DR; Tracy TS
Drug Metab Dispos; 2012 Apr; 40(4):836-42. PubMed ID: 22205778
[TBL] [Abstract][Full Text] [Related]
9. General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information.
Ohno Y; Hisaka A; Ueno M; Suzuki H
Clin Pharmacokinet; 2008; 47(10):669-80. PubMed ID: 18783297
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance.
Wang B; Wang J; Huang SQ; Su HH; Zhou SF
Curr Drug Metab; 2009 Sep; 10(7):781-834. PubMed ID: 19925388
[TBL] [Abstract][Full Text] [Related]
11. CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians.
Vianna-Jorge R; Perini JA; Rondinelli E; Suarez-Kurtz G
Clin Pharmacol Ther; 2004 Jul; 76(1):18-26. PubMed ID: 15229460
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo.
Ufer M; Kammerer B; Kahlich R; Kirchheiner J; Yasar U; Brockmöller J; Rane A
Xenobiotica; 2004 Sep; 34(9):847-59. PubMed ID: 15742978
[TBL] [Abstract][Full Text] [Related]
13. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers.
Kirchheiner J; Meineke I; Müller G; Bauer S; Rohde W; Meisel C; Roots I; Brockmöller J
Clin Pharmacokinet; 2004; 43(4):267-78. PubMed ID: 15005635
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome p450 polymorphisms in geriatric patients: impact on adverse drug reactions--a pilot study.
Egger T; Dormann H; Ahne G; Pahl A; Runge U; Azaz-Livshits T; Neubert A; Criegee-Rieck M; Gassmann KG; Brune K
Drugs Aging; 2005; 22(3):265-72. PubMed ID: 15813658
[TBL] [Abstract][Full Text] [Related]
15. S-warfarin limited sampling strategy with a population pharmacokinetic approach to estimate exposure and cytochrome P450 (CYP) 2C9 activity in healthy adults.
Tran L; Nikanjam M; Capparelli EV; Bertino JS; Nafziger AN; Kashuba ADM; Turpault S; Ma JD
Eur J Clin Pharmacol; 2021 Sep; 77(9):1349-1356. PubMed ID: 33754183
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms of human cytochrome P450 2C9 and the functional relevance.
Zhou SF; Zhou ZW; Huang M
Toxicology; 2010 Dec; 278(2):165-88. PubMed ID: 19715737
[TBL] [Abstract][Full Text] [Related]
17. Quantitative Prediction of Drug Interactions Caused by CYP1A2 Inhibitors and Inducers.
Gabriel L; Tod M; Goutelle S
Clin Pharmacokinet; 2016 Aug; 55(8):977-90. PubMed ID: 26936044
[TBL] [Abstract][Full Text] [Related]
18. A Quantitative Approach to the Prediction of Drug-Drug Interactions Mediated by Cytochrome P450 2C8 Inhibition.
Di Paolo V; Ferrari FM; Poggesi I; Quintieri L
Expert Opin Drug Metab Toxicol; 2021 Nov; 17(11):1345-1352. PubMed ID: 34720033
[TBL] [Abstract][Full Text] [Related]
19. Limitations of S-warfarin truncated area under the concentration-time curve to predict cytochrome P450 2c9 activity.
Wu JC; Nafziger AN; Bertino JS; Ma JD
Drug Metab Lett; 2012 Jun; 6(2):94-101. PubMed ID: 22594566
[TBL] [Abstract][Full Text] [Related]
20. Impact of CYP2C19 and CYP2C9 gene polymorphisms on sodium valproate plasma concentration in patients with epilepsy.
Song C; Li X; Mao P; Song W; Liu L; Zhang Y
Eur J Hosp Pharm; 2022 Jul; 29(4):198-201. PubMed ID: 32868386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
